4
Wire-neutral
provisional
✓ No loaded language, vague sourcing, or framing detected.
FDA mandates warning labels for GLP-1 medications due to risk of rare eye condition
The FDA has mandated that all GLP-1 medications include warnings about a rare eye condition that can cause blindness. This requirement affects drugs such as Ozempic, Wegovy, and Mounjaro.
Companies
Novo Nordisk
Eli Lilly
Sanofi
Our neutral summary
The FDA has mandated that all GLP-1 medications include warnings about a rare eye condition that can cause blindness. This requirement affects drugs such as Ozempic, Wegovy, and Mounjaro.
Read the full story at Guardian — US ↗
The reporting belongs to
Guardian — US;
we don't reproduce it.